Angle Share Discussion Threads

[banshee] 07/1/2024 20:06

Interesting fairly recent (2021) paper, again re a numer of different approaches and companies, Parsortix comes out reasonably.



"The Parsortix (Angle) device has been developed with a chip containing a stepped/gradiated separation structure that gradually decreases with size, with final gap sizes ranging from 4.5 μm to 10 μm. The most common GEN3D6.5 Cell Separation Cassette has a “critical gap” size of 6.5 µm which acts to capture larger CTCs and allows other smaller, more deformable blood components to pass through [113]. The device is fairly slow at processing, taking ~4 h for 7.5 mL blood and is only semi-automated, requiring significant user input. Following cell capture, a reverse pressure is then applied to harvest the CTCs. The device is able to capture CTC clusters and there is the option for on-chip staining, however on chip imaging is difficult. Using the 6.5 µm gap size cassette, an average capture rate of 62.4% was achieved across breast- and NSCLC-derived cell lines, however purity decreases as the cassette “critical gap” size decreases [35]. The system is well suited to enrich CTCs from clinical samples (although harvested cells are not pure CTCs), taking advantage of the different physical properties (i.e., size and deformability) of the target rare cells compared to other blood components such as RBCs and WBCs."

[bones699] 07/1/2024 19:52

5oleTrader.

Really.....read the RNS again...slowly this time.....only 47 test subjects.

That doesn't meet the FDA minimum approval requirement...AGL needs constant testing and results from thousands of test subjects not a mere 47!

Where were the financial figures nothing released..go figure it's hype and will take months of testing before FDA grant formal approval.

AGL only has FDA approval for breast cancer testing...

[5oletrader] 07/1/2024 19:10

Listen closely to 2m52s - "from our point of view screening or quantifying a larger number of MUTATIONs would be a more ACCURATE approach than only quantifying specific hotspots" https://youtu.be/gWbK4WxyMz0?si=ww0i3h-uB61ovse_-Take the above and realise it only applies to ctDNA (dead cells).-Why did the share price go ballistic? BECAUSE Widely accepted actionable DNA variants (cancer MUTATIONs) were IDENTIFIED in CTCs that were NOT PRESENT in the ctDNA from the SAME BLOOD DRAW in 70% of breast cancer patient samples, 70% of lung cancer patient samples and 60% of ovarian cancer patient samples. KEY POINT - if screening/quantifying MUTATIONs is to provide a more ACCURATE APPROACH - then AGL just knocked the ball out the park!-I think @Miavoce likes to throw numbers around - so here's something to play with. Two (2) trials are mentioned in the above vid - NADIM II and ADAURA. In the context of patient monitoring (cassette sales) maybe these are potential timelines?•Before treatment •After treatment •Every 3 months during the 1st year•Every 4 months during the 2nd year•Every 6 months thereafter-NADIM II Trial:https://www.nejm.org/doi/full/10.1056/NEJMoa2215530ADAURA Trial:https://www.nejm.org/doi/full/10.1056/NEJMoa2304594-Why post the trials?NOTE - Key Market Players in trial Funding.NADIM II - Funded by Bristol Myers Squibb and othersADAURA - Funded by AstraZeneca.-Will Key Market Players be interested in AGLs clinical study results? Can't be ignored IMO.-ATB

[miavoce] 07/1/2024 18:58

Not trying to lure anybody in, just setting out why investors won't need to wait a decade for a good return (as was being stated by some posters).

[bones699] 07/1/2024 18:49

Think the share price will close down 25% tommorrow as the price bubble continues to deflat from Friday and the market realises AGL still hasn't made any material revenues just a single 'peanut' sized commercial deal for just $250k!...All the rest of that RNS was just background noise and more hype!

[bones699] 07/1/2024 18:46

K..

Hmm yes they were in a position to trade they could have done this several weeks ago if they were that confident..Last weeks RNS was light on financials just a small $250k contract so yes Directors could have bought shares but chose not to there were no restrictions on them.

[mrkeysersoze] 07/1/2024 15:35

Do you seriously think, that given last weeks fantastic news the BOD where in a position to buy ? Given the nature of the last 2 reported news releases, the BOD would have not been in a position to make further share purchases.I'm sorry this response, destroys your post, but first day at school springs to mind!!!!Please try harder.Mr K.

[s34icknote] 07/1/2024 14:40

Angle have proved they can win 250k dollar contracts They have withdrawn labs in US and are picking up small servicing contracts .The deals to make them self financing have yet made it to the table . I hope they make it for patients sakes

[phatstyle321] 07/1/2024 13:40

Angle have released 2 stella RNS’s last week and investors have reacted to it.

They will most likely bring another out before Thursday and it has been confirmed they have £15m plus in the bank so if there is no capital raise RNS on Monday it will jump back up


Also talks with Illumina have progressed and a RNS to know deals terms before Thursday would be cherry on top.

Angle has proved that it’s technology works and will be north of its depressed SP, Monday could be a 25-50% gain day easy

[astra1vision] 07/1/2024 13:34

Another muppet trying to lure in mug punters. Let’s chat again on Friday. It will be fun.

[miavoce] 07/1/2024 13:26

astra1vision

2024 is IMO the year when Angle's commercial transformation will be clear for all to see, no need to wait a decade to see a good return on the share price (although feel free to stay uninvested / short).

I see the de-ramping playbook is widely in use at the moment - the 'no director buying' is an old favourite isn't :-)

Not that it matters what is said on these boards anyway as the volume of trading over Thu / Fri was at a level way beyond normal PI trading, so it would appear that there is institutional interest.

[astra1vision] 07/1/2024 13:21

I agree this may fly, perhaps in another decade or so. When directors don’t buy at 10p you know something isn’t right. All I can say to the rampers is let’s see the price in a few days. Humble pie comes to mind. Zeus, bones and their disciples will be eating plenty.

[miavoce] 07/1/2024 13:17

What can Angle make money from now / very soon:-

1. Their own pharma labs supporting pharma drug trials - this business will IMO grow substantially as new assays come on line and as a result of the the latest announcement ref ctDNA and CTC's

2. Selling machines, cassettes and kits to CLIA labs that wish to offer services to pharma's in support of drug trials - IMO this will grow quickly as the demand from pharma for CTC analysis alongside ctDNA analysis builds

3. Machine, cassette and kit sales to research labs worldwide - the scaling up of the distributor network and the increasing availability of assays will drive this growth

4. Undertaking ovarian and prostate testing from their own lab - should come on stream in H1 this year

5. Selling machines, cassettes and kits to CLIA labs that wish to offer ovarian and prostate testing

The above is enough to generate very substantial income and should see year on year multiple increase in sales revenue hereafter.

And then on top of this will be income from commercial partnerships as and when they are established.

Further out it is highly likely that parsortix will be used in companion diagnostics for drugs targeting specific mutations (particularly where parsortic has been used in the trials of those drugs).

And in the longer term there are all sorts of additional possibilities in the clinical space.

So, IMO, both the immediate and long term future is very bright. I believe that this will become increasingly apparent in 2024 and the share price will respond accordingly.

[gurunostradamus] 07/1/2024 11:52

….only time will…the news flow has thus far brought it from sub 10p to 37p high… the momentum remains positive..the long term investors just need to remain patient..any possible equity raise will be more than likely when the share price is above 50p and by last quarter if at all.. in the meantime just ignore the people with not so hidden agendas..

[gooosed] 07/1/2024 11:51

Angle confirmed (July last year) that IF successful, the Prostate collaboration trial with Solaris Health/MidLantic (900,000 patients annually) would see the initial launch of a prostate test in either Q1 or Q2 this year :

From 47:57

I suspect & as mentioned before, that initial self pay route by 5% of their patient base is realistic given the discomfort, inaccuracy & potential hazards of the alternative surgical route.

Prostate results are now due.

In the same presentation use of Parsortix in other indications is covered from 36.05

[bones699] 07/1/2024 11:46

Yeh only breast cancer though and clearance for what further testing in the USA through clinically approved labs?

TR-1 notices normally follow if there have been any large share movements by a major investor, new or existing, we should see soon enough.

[gspanner] 07/1/2024 11:24

Over the years I have been convinced that unfortunately all the rubbish and obfuscation above does cast doubt and sadly affect confidence.

EVERYONE posting on a bb has an agenda whether they admit it or not. No one posts out of altruism. It may be sour grapes having missed the rise/lost money , may be wanting to depress the share price to get in cheaper or more likely organised shorters. None of it is objective.

I do draw comfort from the fact that 80m shares bought and sold wasn’t spivvy traders… Someone/some institution/institutions have bought a lot. We remain to see who but there must be a change in holdings to be announced soon.

Quite a few folk are wasting their Sunday trying to discourage people from investing… Probably says more than anything really!

[con90210] 07/1/2024 11:22

Let's see what the opening brings tomorrow...I feel up first thing and then settle around the 25p mark.

[bones699] 07/1/2024 10:46

Zeus19

Because they don't they only have £13m left cash burn over £1.5m per month.

That's why they closed the US laboratory to save costs but not much good if you expect sales in the US to rocket which need lab support services.

Check June 23 reported cash position £22m how much left in the kitty now, c.£13m or 8 months of cash left?

Certainly not enough cash to see them through to H2 2025, that's a blatant lie!

They also need to meet the 'Going Concern' concept by having at least 12 months of cash left for the auditors to sign off the year end accounts for Dec 2023 in May 2024...They don't have £18m of cash, FACT!!

[zeus19] 07/1/2024 10:45

I think you need to educate yourself a bit more...

[zeus19] 07/1/2024 10:44

Why would they raise when they have sufficient capital until H2 2025? If there was a fundraise coming, I would imagine it coming towards the end of this year by which point they may not even need one of commercial deals materialise